Clinical Trial Update: A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing exenatide with basal insulin to achieve target HbA1c with minimal weight gain in type 2 diabetes; results were posted after study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Basal insulin (basal insulin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2009-06-05